Celgene Corporation Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (4)

Latest Articles

About This Stock More About This Stock
EC Holiday Fever Takes Hold Of Stock Investors, But A Pullback Is Needed
Article By: Sabrient Systems
Monday, November 24, 2014 3:15 PM EDT
Nothing goes up in a straight line, not even during the holidays, so a near-term market pullback would be a healthy way to prevent a steeper correction in January.
In this article: AGN, TXN, UPS, XTN, SOXX, AMGN, CELG, INTC, LSTR, BBH, SPY, VIX, ACT
Read
OMED Offers Data From Demcizumab; CELG Receives Positive CHMP Opinion For OTEZLA
Article By: BioMedReports
Monday, November 24, 2014 3:23 AM EDT
OMED a clinical-stage company presenting data in two posters, highlighting the company's translational research and biomarker efforts for its tarextumab. CELG announced that the (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA.
In this article: CELG, OMED
Read
Hot Bargains In Big Biotech
Article By: Bret Jensen
Tuesday, November 18, 2014 12:00 PM EDT
It has been an eventful year in the big pharma and biotech space, and a lot is happening in this space that biotech investors should take note of.
In this article: AGN, AVNR, REGN, AMGN, BIIB, CELG, GILD, ABBV
Read
StockTwits Top 10 Lags Market
Article By: Blair Jensen
Friday, November 7, 2014 2:15 PM EDT
StockTwits Top 10 portfolio lagged the market. The under performance was mostly a result of a nearly 20% decline from First Solar. Celgene was the only outstanding winner up 12%.
In this article: AA, WLT, XOM, FSLR, CELG, GMCR, MSFT, YHOO, BABA
Read
Consider The 2-3x Upside In This Most Overlooked Hepatitis B Stock
Article By: PropThink
Tuesday, November 4, 2014 1:32 PM EDT
GlobeImmune IPO’d in June to little fanfare and has underperformed the biotech sector considerably since then. A key driving event in the next six months should put it back on the radar.
In this article: ALNY, CELG, GILD, ARWR, GBIM
Read
Being Early On An Early Asset: Trillium May Be A Diamond In The Rough Immunotherapy Stock
Article By: PropThink
Wednesday, October 29, 2014 9:59 AM EDT
Trillium Therapeutics is an immuno-oncology company developing novel cancer therapeutics. Their primary target, the CD47 antigen, is generating significant attention from industry and academia alike.
In this article: SCTPF, CELG
Read

Latest Tweets for $CELG

No tweets yet!